$INMD

InMode Ltd. (INMD): Financial results for Q2 2026

InMode Ltd. (INMD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025 YOKNEAM, Israel, August 5, 2026 - InMode Ltd. (Nasdaq: INMD) (“InMode”) , a leading global provider of innovative medical techno

Original reporting
Published Aug 5, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 7:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$INMD
Bearish
high confidence
Mentioned
$INMD
Relevance
7/10
alphai data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$INMDBearishMed
01

Why it matters

The earnings release shows flat revenue, margin compression, and modest guidance, likely prompting a sell‑off.

02

Market read

Primary earnings disclosure for a small‑cap biotech/med‑tech stock; relevant for traders tracking earnings momentum.

03

What to watch

Record consumables revenue in Asia and ongoing share repurchase may provide longer‑term support.

Relevance 7/10Novelty 8/10Timing: post‑market release on Aug 5 2026

Background

InMode Ltd., a Nasdaq‑listed medical‑technology company, filed a Form 6‑K reporting its Q2 2026 results and FY guidance.

Company-level read

Ticker impact

$INMDBearishHigh confidence
Context

Q2 2026 GAAP revenue of $95.6M and FY 2026 guidance of $365‑$375M were disclosed for the first time.

Expected impact

Potential short‑term downside as investors digest weaker margins and modest guidance.

Evidence & confidence

Revenue unchanged YoY and operating margin fell from 24% to 13% (GAAP) signal slower growth; guidance remains below prior expectations.

Market effects

Medical‑device sector may see broader scrutiny of margin pressures.

Limited to U.S. and Israeli markets where InMode operates.

Minimal global impact; primarily affects InMode shareholders.

Counterpoint

Despite margin decline, cash position of $501M could fund strategic acquisitions and support upside.

Key entities

  • InMode Ltd.

    Nasdaq‑listed medical‑technology firm.

  • Moshik Itzkovich

    Chief Financial Officer who commented on results.

Related articles

$INMDMedAI 8/10

InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025

InMode Ltd. (Nasdaq: INMD) reported Q2 2026 GAAP revenues of $95.6M, unchanged vs Q2 2025. Consumables and service rose 13% to $22.3M. GAAP net income was $17.1M ($0.29/diluted share). Cash and equivalents plus marketable securities totaled $501.1M at June 30, 2026. FY2026 outlook: revenues $365M-$375M and non-GAAP EPS $1.29-$1.34.

$INMDMed

InMode Confirms Receipt of Unsolicited Proposal

InMode Ltd. (NASDAQ: INMD) said its board received an unsolicited acquisition proposal from Steel Partners Holdings L.P., dated July 9, 2026. A special committee of independent directors will review the proposal with legal and financial advisors. The committee said it will not comment further for now.

$INMDMedAI 9/10

InMode Shares Jump After Steel Partners Tables Higher Takeover Proposal (INMD)

InMode Ltd (INMD) shares rose about 4% premarket after Steel Partners Holdings proposed to buy the medical aesthetics company for $16.75 per share in cash, a 20% premium to $13.95 and above a prior $16.20 bid by CEO Moshe Mizrahy. Steel Partners urged an independent committee, questioned governance and possible MNPI around share purchases, and cited 2026 adj. EBITDA of $65M vs guidance $73M-$78M.

$INMDHighAI 9/10

InMode stock surges on Steel Partners’ $16.75 buyout offer By Investing.com

InMode Ltd (NASDAQ:INMD) shares rose about 4% premarket after Steel Partners Holdings offered to buy the company for $16.75 per share in cash. Steel Partners, a major shareholder, cited a 20% premium to $13.95 and said it would allow rollover of up to 40% of equity into Steel-owned InMode. It urged an independent committee, challenged CEO Moshe Mizrahy, and referenced 2026 adjusted EBITDA of $65 million versus guidance of $73 million to $78 million.

$IBKRMedAI 8/10

Interactive Brokers Earns Interest on $182 Billion of Its Clients' Idle Cash. Will Anthropic's IPO Drain It?

Interactive Brokers (IBKR) reported $182.4B in uninvested client cash, up 27% YoY, earning interest until invested. Anthropic's potential $2T IPO could impact cash levels, but SpaceX's IPO didn't drain IBKR's reserves. IBKR's Q2 net interest income rose 23% to $1.06B, half of total revenues. Client accounts and trading activity grew, mitigating cash outflows. IBKR stock is near $92, trading at 29x next year's earnings.

$ORCLMedAI 8/10

Oracle’s AI Earnings Story Is Improving, but the Cash Flow Test Remains

Oracle (ORCL) reported strong Q4 earnings with 21% revenue growth and raised its profit forecast. Morgan Stanley increased its price target to $210, citing improved GPUaaS margins. However, the company faces cash flow pressure due to high capital expenditures for AI infrastructure, with free cash flow at negative $23.7 billion. Hedge funds remain invested, with Fisher Asset Management increasing its stake.